neotiv
Alzheimer’s research and patient-centered digital care
About neotiv
Enabling cognitive health
neotiv GmbH develops digital biomarkers for the early detection of neurodegenerative diseases, first and foremost Alzheimer’s disease. These form the basis for innovative cognitive tests that, embedded in a user-friendly software platform, support the diagnosis and care process.
As a spin-off of Otto-von-Guericke University Magdeburg (OvGU) in close cooperation with the German Center for Neurodegenerative Diseases (DZNE), the company draws on the latest neuroscientific findings.
Management
bmp Ventures Team
Founded
2017
Invested
2021
Stage
Start-up
Industry
Life Sciences & eHealth
Status
Aktiv